Fennec Pharmaceuticals Inc. (FENC) vs Opus Genetics, Inc. (IRD)
A side-by-side comparison of Fennec Pharmaceuticals Inc. and Opus Genetics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
FENC
Fennec Pharmaceuticals Inc.
$10.30HealthcareDelayed quote: Oct 6, 2026, 11:05 AM EDT
IRD
Opus Genetics, Inc.
$4.30HealthcareDelayed quote: Oct 6, 2026, 11:05 AM EDT
Total return — FENC vs IRD
growth of $100 · dividends reinvested · last 2yFENC +119.0% (+48.0%/yr)IRD +239.5% (+84.3%/yr)IRD compounded faster over this window
FENC IRD
FENC vs IRD: by the numbers
- •FENC is the larger company ($358M vs $355M market cap).
- •Both run net losses; FENC's is the smaller (-5.49% vs -1091.82% net margin).
- •FENC grew revenue faster over the past five years (222.46% vs 150.49% CAGR).
Metrics side by side
Valuation
| Metric | FENC | IRD |
|---|---|---|
| Forward P/E | 36.35 | N/A |
| P/S ratio | 6.04 | 36.02 |
| P/B ratio | 8.43 | N/A |
Profitability
| Metric | FENC | IRD |
|---|---|---|
| Gross margin | 93.73% | 99.87% |
| Operating margin | -14.22% | -271.90% |
| Net margin | -5.49% | -1091.82% |
| ROE | -7.66% | N/A |
| ROIC | -1.84% | -59.29% |
Growth (annualized)
| Metric | FENC | IRD |
|---|---|---|
| Revenue CAGR (5Y) | 222.46% | 150.49% |
| Total return CAGR (5Y) | 2.45% | N/A |
Frequently asked
- Which has grown faster, FENC or IRD?
- Over the past five years, FENC grew revenue faster — FENC at a 222.46% CAGR versus IRD at 150.49%.
Go deeper
Dig into the metrics
Fennec Pharmaceuticals ROEOpus Genetics ROEFennec Pharmaceuticals operating marginOpus Genetics operating marginFennec Pharmaceuticals revenue growthOpus Genetics revenue growthFennec Pharmaceuticals free cash flowOpus Genetics free cash flow
Fennec Pharmaceuticals & Opus Genetics appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.